Journal Home
Access this journal onSciVerse ScienceDirect
Visit SciVerse ScienceDirect to see if you have access via your institution.
Search for
Advanced Search - MEDLINE - My Recent Searches - My Saved Searches - Search Tips
More periodicals:

Volume 5, Issue 1, Page 12 (January 2010)


View previous. 13 of 43 View next.

PREVIEW

FULL TEXT

FULL-TEXT PDF (140 KB)

CITATION ALERT

CITED BY

EXPORT CITATION

EMAIL TO A COLLEAGUE

RIGHTS/PERMISSIONS

NEED REPRINTS?

ONJ Less Than 1% With Bevacizumab

BRUCE JANCIN

SAN ANTONIO — The largest-ever analysis of osteonecrosis of the jaw occurring in women receiving the antiangiogenesis agent bevacizumab for advanced breast cancer indicates the incidence is less than 1%, even in patients receiving bisphosphonates.

PII: S1558-0164(10)70013-4

doi:10.1016/S1558-0164(10)70013-4


View previous. 13 of 43 View next.

Copyright © 2012 Elsevier Inc. All rights reserved. | Privacy Policy | Terms & Conditions | Feedback | About Us | Help | Contact Us |
The content on this site is intended for health professionals.